ASH 2025 preview – Kelonia gets a late-breaking coup
An in vivo Car-T produced a 100% response rate – in three patients.
Astra gives in vivo Car-T its biggest endorsement
The company buys Belgium’s EsoBiotec for $425m.
Umoja and AbbVie chase Interius with in vivo Car-T
The companies hope to be as efficacious as ex vivo therapy, with convenience and safety advantages.
